Valuation: Immutep Limited

Market Cap 48.63M 33.67M 29.9M 27.96M 25.48M 47.97M 3.24B 338M 131M 1.65B 126M 124M 5.3B P/E 2027 *
-1.94x
P/E 2028 * -3x
Enterprise Value -5.97M -4.13M -3.67M -3.43M -3.13M -5.89M -398M -41.51M -16.07M -203M -15.51M -15.17M -651M EV / Sales 2027 *
-1.49x
EV / Sales 2028 * 4.93x
Free-Float
96.87%
Yield 2027 *
-
Yield 2028 * -
1 day-3.03%
1 week-11.11%
Current month-5.88%
1 month-34.69%
3 months-42.86%
6 months-27.27%
Current year-92.29%
1 week 0.03
Extreme 0.0305
0.04
1 month 0.03
Extreme 0.0305
0.06
Current year 0.03
Extreme 0.028
0.47
1 year 0.03
Extreme 0.028
0.47
3 years 0.03
Extreme 0.028
0.48
5 years 0.03
Extreme 0.028
0.71
10 years 0.03
Extreme 0.028
0.72
Manager TitleAgeSince
Chief Executive Officer 53 2014-07-08
Director of Finance/CFO - 2018-02-28
Chief Tech/Sci/R&D Officer - 2025-06-30
Director TitleAgeSince
Director/Board Member 53 2014-07-08
Chairman 76 2017-11-16
Director/Board Member 57 2014-02-11
Date Insider Type Main position Quantity % Market Cap. Importance
3/18/26 Other

Chief Technology Officer

14,224,374 0.9652%
3/18/26 Other

Executive/Senior Manager

5,174,048 0.3511%
3/18/26 Other

Chief Executive Officer

18,477,395 1.2538%
Change 5-day change 1-year change 3-year change Capi.($)
-3.03%-11.11%-88.57%-88.77% 33.67M
+4.16%+3.04%+49.37%+94.17% 74.41B
-1.16%-1.59%+24.37%+78.12% 59.26B
+0.75%-0.53%+4.39%+34.65% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.82%-1.79%+38.70%+129.80% 39.25B
Weighted average by Cap. -0.03%-0.32%+58.00%+145.74%

Financials

2027 *2028 *
Net sales 4M 2.77M 2.46M 2.3M 2.1M 3.95M 267M 27.82M 10.77M 136M 10.4M 10.17M 436M 3M 2.08M 1.84M 1.72M 1.57M 2.96M 200M 20.87M 8.08M 102M 7.8M 7.63M 327M
Net income -26.1M -18.07M -16.05M -15.01M -13.68M -25.75M -1.74B -182M -70.28M -886M -67.83M -66.36M -2.85B -30.47M -21.1M -18.74M -17.52M -15.97M -30.06M -2.03B -212M -82.06M -1.03B -79.2M -77.48M -3.32B
Net Debt -54.6M -37.8M -33.57M -31.39M -28.61M -53.86M -3.64B -380M -147M -1.85B -142M -139M -5.95B -33.83M -23.42M -20.8M -19.45M -17.73M -33.37M -2.25B -235M -91.1M -1.15B -87.93M -86.03M -3.69B
Logo Immutep Limited
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Employees
31
Date Price Change Volume
26-10-02 A$0.0320 -3.03% 24,951,559
26-10-01 A$0.0330 -2.94% 4,232,785
26-09-30 A$0.0340 0.00% 4,497,329
26-09-29 A$0.0340 0.00% 7,182,179
26-09-28 A$0.0340 -5.56% 17,593,081
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.0330AUD
Average target price
0.1133AUD
Spread / Average Target
+243.42%

Quarterly revenue - Rate of surprise